Selected Slide Presentations
Click on the links below to view presentations.

Plenary
New Achievements in Hepatitis C Virus Research and Their Implications for Antiviral Therapy
Ralf Bartenschlager, University of Heidelberg, Germany

HCV Drug Resistance
Synergy of Small Molecular Inhibitors of Hepatitis C Virus (HCV) Replication Directed at Different Viral Targets
David Wyles, UCSD, USA

Selection and Characterization of Hepatitis C Virus Replicon Variants Dually Resistant to Thumb and Palm Binding Non-Nucleoside Polymerase Inhibitors
Isabel Najera, Roche Palo Alto, USA

Resistance to New Antiretroviral Agents
Identification and Characterization of Novel Reverse Transcriptase Inhibitors
Miguel Quinones-Mateu, Cleveland Clinic Foundation, USA

The In Vitro Resistance Profile of NcRTI-1 is Complementary with the Resistance Profile of Tenofovir and Zidovudine
Dirk Jochmans, Tibotec, Belgium

HIV Pathogenesis, Fitness and Resistance
HBV Drug Resistance
Stephen Locarnini, Victorian Infectious Diseases Reference Laboratory, Australia

Sequential Emergence and Clinical Implications of K70E and K65R Viral Mutants during Prolonged Tenofovir Monotherapy in Rhesus Macaques with Chronic RT-SHIV Infection
Koen Van Rompay, California National Primate Research Center, USA

Selection of Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistant HIV-1 after Discontinuation of a Virologically Suppressive Regimen
Brad Hare, University of California, San Francisco, USA

Impact of Enfuvirtide Resistance Genotype on CD4 Increases in Patients with Ongoing Viral Replication while Receiving Enfuvirtide
Tom Melby, Trimeris, Inc., USA

Clinical Implications of Resistance
Allele-Specific PCR Shows Low-Level K65R in Treatment-Experienced Patients with L74V in the Absence of TAMs
Michael Miller, Gilead Sciences, USA

Defining Lower (L) and Upper (U) Phenotypic Clinical Cutoffs (CCO’s) for Tipranavir (TPV), Lopinavir (LPV), Saquinavir (SQV) and Amprenavir (APV) Co-administered with Ritonavir (r) within the RESIST Dataset using the PhenoSense Assay (Monogram (MGRM) Biosciences)
Eoin Coakley, Monogram Biosciences, USA

Mechanisms of HIV Drug Resistance
The HIV-1 Reverse Transcriptase Connection Domain From Treatment-Experienced Patients Contributes to AZT Resistance
Krista Frankenberry, HIV Drug Resistance Program, USA

Infrequent Occurrence of Mutations in the C-terminal Region of Reverse Transcriptase Modulates Susceptibility to RT Inhibitors
Soumi Gupta, Monogram Biosciences Inc., USA

Invited Session: Resistance Test Interpretation & Prediction of Clinical Response
Rules & Algorithms, Derivation, Deviation and Validation
Jonathan Schapiro, National Hemophilia Center, Israel